1Schneider, M, Debbané, M, Bassett, AS, Chow, EWC, Fung, WLA, van den Bree, M, et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry 2014; 171(6): 627–39.
2Bassett, AS, Chow, EWC, AbdelMalik, P, Gheorghiu, M, Husted, J, Weksberg, R. The schizophrenia phenotype in 22q11 deletion syndrome. Am J Psychiatry 2003; 160(9): 1580–6.
3Murphy, KC, Jones, LA, Owen, MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 1999; 56(10): 940–5.
4Boot, E, Booij, J, Zinkstok, J, Abeling, N, de Haan, L, Baas, F, et al. Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome. Neuropsychopharmacology 2008; 33(6): 1252–8.
5Gothelf, D, Law, AJ, Frisch, A, Chen, J, Zarchi, O, Michaelovsky, E, et al. Biological effects of COMT haplotypes and psychosis risk in 22q11.2 deletion syndrome. Biol Psychiatry 2014; 75(5): 406–13.
6Barnes, TRE, Mutsatsa, SH, Hutton, SB, Watt, HC, Joyce, EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 2006; 188(3): 237–42.
7Young, SE, Corley, RP, Stallings, MC, Rhee, SH, Crowley, TJ, Hewitt, JK. Substance use, abuse and dependence in adolescence: prevalence, symptom profiles and correlates. Drug Alcohol Depend 2002; 68(3): 309–22.
8Chambers, RA, Krystal, JH, Self, DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001; 50(2): 71–83.
9Volkow, ND. Substance use disorders in schizophrenia--clinical implications of comorbidity. Schizophr Bull 2009; 35(3): 469–72.
10Korver, N, Quee, PJ, Boos, HBM, Simons, CJP, de Haan, L. Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int J Methods Psychiatr Res 2012; 21(3): 205–21.
11First, MB, Gibbon, M. The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and the Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II). John Wiley & Sons Inc, 2004.
12Kaufman, J, Birmaher, B, Brent, D, Rao, U, Flynn, C, Moreci, P, et al. Schedule for affective disorders and schizophrenia for school-age children - present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36: 980–8.
13Sheenan, D, Lecrubier, Y, Sheenan, K, Amorim, P, Janavs, J, Weiler, E. The MINI-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: 22–33.
14Prosser, H, Moss, S, Costello, H, Simpson, N, Patel, P, Rowe, S. Reliability and validity of the Mini PAS-ADD for assessing psychiatric disorders in adults with intellectual disability. J Intellect Disabil Res 1998; 42: 264–72.
15Andreasen, NC. The comprehensive assessment of symptoms and history (CASH). Arch Gen Psychiatry 1992; 49: 615.
16Robins, LN. The Composite International Diagnostic Interview. Arch Gen Psychiatry 1988; 45(12): 1069.
17Wechseler, D. WAIS-III: Wechsler Adult Intelligence Scale, third ed. Administration and Scoring Manual. Psychological Corporation, 1997.
18Wechseler, D. Manual for the Wechsler Intelligence Scale for Children-(WISC-III). Psychological Corporation, 1991.
19Velthorst, E, Levine, SZ, Henquet, C, de Haan, L, van Os, J, Myin-Germeys, I, et al. To cut a short test even shorter: reliability and validity of a brief assessment of intellectual ability in schizophrenia – a control-case family study. Cogn Neuropsychiatry 2013; 18: 574–93.
20Bassett, AS, Caluseriu, O, Weksberg, R, Young, DA, Chow, EWC. Catechol-O-methyl transferase and expression of schizophrenia in 73 adults with 22q11 deletion syndrome. Biol Psychiatry 2007; 61(10): 1135–40.
21Vorstman, JAS, Turetsky, BI, Sijmens-Morcus, MEJ, de Sain, MG, Dorland, B, Sprong, M, et al. Proline affects brain function in 22q11DS children with the low activity COMT 158 allele. Neuropsychopharmacology 2009; 34(3): 739–46.
22van Duin, EDA, Goossens, L, Hernaus, D, da Silva Alves, F, Schmitz, N, Schruers, K, et al. Neural correlates of reward processing in adults with 22q11 deletion syndrome. J Neurodev Disord 2016; 8: 25.
23Angkustsiri, K, Leckliter, I, Tartaglia, N, Beaton, EA, Enriquez, J, Simon, TJ. An examination of the relationship of anxiety and intelligence to adaptive functioning in children with chromosome 22q11.2 deletion syndrome. J Dev Behav Pediatr 2012; 33(9): 713–20.
24Roberti, JW. A review of behavioral and biological correlates of sensation seeking. J Res Pers 2004; 38(3): 256–79.
25Harden, KP, Quinn, PD, Tucker-Drob, EM. Genetically influenced change in sensation seeking drives the rise of delinquent behavior during adolescence. Dev Sci 2012; 15(1): 150–63.
26Compton, WM, Conway, KP, Stinson, FS, Colliver, JD, Grant, BF. Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2005; 66(6): 677–85.
27Raina, P, Lunsky, Y. A comparison study of adults with intellectual disability and psychiatric disorder with and without forensic involvement. Res Dev Disabil 2010; 31(1): 218–23.
28Berridge, KC, Robinson, TE. Parsing reward. Trends Neurosci 2003; 26(9): 507–13.
29van Hell, H, Vink, M, Ossewaarde, L, Jager, G, Kahn, R, Ramsey, N. Chronic effects of cannabis use on the human reward system: an fMRI study. Eur Neuropsychopharmacol 2010; 20(3): 153–63.
30Martz, ME, Trucco, EM, Cope, LM, Hardee, JE, Jester, JM, Zucker, RA, et al. Association of marijuana use with blunted nucleus accumbens response to reward anticipation. JAMA Psychiatry 2016; 73(8): 838.
31Wrase, J, Schlagenhauf, F, Kienast, T, Wüstenberg, T, Bermpohl, F, Kahnt, T, et al. Dysfunction of reward processing correlates with alcohol craving in detoxified alcoholics. Neuroimage 2007; 35(2): 787–94.
32Esslinger, C, Englisch, S, Inta, D, Rausch, F, Schirmbeck, F, Mier, D, et al. Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients. Schizophr Res 2012; 140(1): 114–21.
33Strauss, GP, Waltz, JA, Gold, JM. A review of reward processing and motivational impairment in schizophrenia. Schizophr Bull 2014; 40(Suppl 2): S107–16.
34Dubourg, L, Schneider, M, Padula, M, Eliez, S. Reward Processes, White Matter Pathways of the Reward System and Negative Symptoms in 22q11DS. Organization for Human Brain Mapping, 2016.
35Chapman SL, C, Wu, L-T. Substance abuse among individuals with intellectual disabilities. Res Dev Disabil 2012; 33(4): 1147–56.
36Swerts, C, Vandevelde, S, VanDerNagel, JEL, Vanderplasschen, W, Claes, C, De Maeyer, J. Substance use among individuals with intellectual disabilities living independently in Flanders. Res Dev Disabil 2017; 63: 107–17.
37van Duijvenbode, N, VanDerNagel, JEL, Didden, R, Engels, RCME, Buitelaar, JK, Kiewik, M, et al. Substance use disorders in individuals with mild to borderline intellectual disability: current status and future directions. Res Dev Disabil 2015; 38: 319–28.
38Chaplin, E, Gilvarry, C, Tsakanikos, E. Recreational substance use patterns and co-morbid psychopathology in adults with intellectual disability. Res Dev Disabil 2011; 32(6): 2981–6.